Thalidomide 4'-oxyacetamide-PEG4-amine |
| Catalog No.GC50463 |
Thalidomide 4'-oxyacétamide-PEG4-amine, un conjugué ligand-lieur E3 ligase synthétisé qui incorpore le ligand cereblon À base de thalidomide et un lieur, peut être utilisé dans la synthèse des PROTAC.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2245697-85-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Functionalized cereblon ligand for PROTAC® research and development; incorporates an E3 ligase ligand plus a PEG linker ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. This product has been recently renamed. The previous name for this product was Thalidomide - linker 2 PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Winter et al (2015) Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348 1376 PMID:25999370 |Salami et al (2017) Waste disposal-An attractive strategy for cancer therapy. Science 355 1163 PMID:28302825
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *